 SAN FRANCISCO, Nov. 4, 2020 PRNewswire -- Nektar Therapeutics NASDAQ:NKTR announced the presentation of additional clinical data from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, currently in development for the... 